Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)-Reference-Cited by-同舟云学术

Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)

Published:2023-02-17 Issue:6 Volume:188 Page:793-794
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Egeberg Alexander¹²^ORCID,Thyssen Jacob P¹

Affiliation:

1. Department of Dermatology, Copenhagen University Hospital – Bispebjerg , Copenhagen , Denmark

2. Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark

Abstract

Recent observational data have suggested an increased risk of cerebrovascular accidents associated with exposure to risankizumab. This article discusses these findings and highlights why there is a need for future observational studies investigating this potential signal.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad039/49650135/ljad039.pdf

Reference6 articles.

1. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials;Gordon;Lancet,2018

2. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – a nationwide cohort study from the DANBIO and DERMBIO registries;Egeberg;Semin Arthritis Rheum,2022

3. GLP-1 receptor agonists and the risk of thyroid cancer;Bezin;Diabetes Care,2023

4. GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS;Yang;Front Pharmacol,2022

5. Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS);Woods;Br J Clin Pharmacol,2022

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Do interleukin-17 and interleukin-23 inhibitors alter the coagulation parameters in psoriasis patients?: A retrospective study;Archives of Dermatological Research;2024-09-11

2. Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials;Dermatology and Therapy;2024-08-17

3. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis;Scientific Reports;2024-03-07

4. Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data;Frontiers in Immunology;2024-02-07

5. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS);Journal of Clinical Medicine;2024-01-16